RUTHERFORD, N.J. & LA JOLLA, Calif. & LOS ANGELES--(BUSINESS WIRE)--Sep 23, 2026--
Lōkahi Therapeutics™ Inc., a subsidiary of Glucotrack, Inc. (NASDAQ: GCTK), today announced that Innovate GBM, a 501(c)(3) nonprofit organization dedicated to accelerating the development of new treatments for glioblastoma (GBM) and other brain tumors, has engaged two ai² PIPELINE project teams to identify and evaluate brain tumor therapeutic assets available for licensing and development. Innovate GBM is the first external organization to secure access to the Lōkahi proprietary asset identification process, which is implemented through its current 14 university collaborations. This engagement marks the ai² Division’s evolution from an internal asset discovery engine to a model capable of supporting the strategic interests of outside organizations.